Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis

Cancer Commun (Lond). 2022 Sep;42(9):902-905. doi: 10.1002/cac2.12320. Epub 2022 Jun 9.

Authors

Yan Xu¹, Yanjun Song², Xiaoyan Liu¹, Yuequan Shi¹, Yingxian Liu², Hao Qian², Xiaoxing Gao¹, Minjiang Chen¹, Ruili Pan¹, Jing Zhao¹, Wei Zhong¹, Wei Wu², Mengzhao Wang¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, P. R. China.
² Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, P. R. China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects
Myocarditis* / chemically induced

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors